Target, Home Depot,...
Health Care: Drugs
Tekmira Pharmaceuticals Corporation (TKMR: NASDAQ)
$4.73 -0.01 | -0.21%
05/17/13 - 03:59 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 47.03M | 9.00M | 12.34M | 23.30M |
| Receivables | 1.08M | 1.37M | 3.72M | 1.27M |
| Inventories | 0.00 | 0.00 | 150.71K | 0.00 |
| Other Current Assets | 2.37M | 0.00 | 817.33K | 0.00 |
| Total Current Assets | 51.25M | 11.55M | 17.91M | 24.79M |
| Property, Plant & Equipment, Gross | 13.19M | 18.30M | 18.67M | 14.61M |
| Accumulated Depreciation & Depletion | 11.84M | 16.15M | 15.55M | 11.93M |
| Property, Plant & Equipment, Net | 1.35M | 2.15M | 3.11M | 2.69M |
| Intangibles | 0.00 | 0.00 | 0.00 | 14.47M |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 1.35M | 2.15M | 3.11M | 17.16M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 52.60M | 13.70M | 21.02M | 41.95M |
| Accounts Payable | 3.80M | 3.89M | 6.15M | 2.00M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 4.02M | 200.83K | 0.00 | 0.00 |
| Total Current Liabilities | 10.96M | 6.84M | 8.13M | 6.51M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 722.51K | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 1.66M | 2.16M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 722.51K | 1.66M | 2.16M | 0.00 |
| Total Liabilities | 11.68M | 8.50M | 10.29M | 6.51M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 40.92M | 5.21M | 10.73M | 35.44M |
| Common Par | 239.48M | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 31.68M | 258.73M | 259.60M | 247.31M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -230.25M | -253.52M | -248.87M | -211.87M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 40.92M | 5.21M | 10.73M | 35.44M |
| Total Equity | 40.92M | 5.21M | 10.73M | 35.44M |
| Total Liabilities & Stock Equity | 52.60M | 13.70M | 21.02M | 41.95M |
| Total Common Shares Outstanding | 14.31M | 12.15M | 10.34M | 10.33M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 13.73M | 11.32M | 10.33M | 10.33M |
| Diluted Weighted Shares Outstanding | 14.32M | 11.32M | 10.33M | 10.33M |
| Number of Employees | 57 | 74 | 94 | 81 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with TKMR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest TKMR Headlines from TheStreet
- Tekmira Announces Election Of Directors 05.17.13 | 06:05 pm
- Tekmira Presents LNP Technology Innovations At Scientific Symposium 05.15.13 | 04:05 pm
- Tekmira Provides Corporate Update And Announces First Quarter 2013 Results 05.14.13 | 04:05 pm
- Tekmira Conference Call And Webcast Advisory: Corporate Update And First Quarter Financial Results 05.09.13 | 08:05 am
- Tekmira Provides Update On U.S. Government Sponsored TKM-Ebola Program 05.08.13 | 08:05 am
- Tekmira's Collaborators At The National Cancer Institute Present Preclinical Data At The Annual Meeting Of The American Association For Cancer Research (AACR) 04.10.13 | 08:04 am
- Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial At American Association For Cancer Research (AACR) Meeting 04.09.13 | 03:04 pm
- Tekmira Provides Corporate Update And Announces Year-End Audited 2012 Results 03.27.13 | 04:03 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Tekmira Conference Call And Webcast Advisory: Corporate Update And Year-End 2012 Financial Results 03.20.13 | 04:03 pm
Press Releases for TKMR
Partner Headlines for TKMR
- Tekmira Says Expects to Receive Notice by Sept 30 on DoD's Decision Related to Order on TKM-EBOLA Program - Benzinga 08.31.12 | 04:08 pm
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Tekmira Provides Periodic Update to Litigation; Alnylam Pharma Files Suit Against Tekmira - Benzinga 01.17.12 | 04:01 pm
- Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia - Benzinga 01.10.12 | 04:01 pm
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- Tekmira and Collaborators Present Data at the AACRMeeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1 - Benzinga 04.04.11 | 04:04 pm
- Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information - Benzinga 03.16.11 | 04:03 pm
